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Glucose-6-phosphate dehydrogenase (G-6-PD) is an enzyme in the pentose phosphate pathway (PPP) which reduces 
NADP to NADPH while oxidizing glucose-6-phosphate. In turn, NADPH then provides reducing equivalents 
needed for the conversion of oxidized glutathione to reduced glutathione, which protects against oxidant injury. The 
activity of G-6-PD was determined in type 2 diabetes mellitus patients and control subjects using enzymatic 
colourimetric method. A total of one hundred (100) subjects consisting of sixty (60) diabetes mellitus patients (test) 
and forty (40) apparently healthy subjects (control) were involved in the study. The mean ± standard deviation of G-
6-PD activity in type 2 diabetic patients was 2.53±1.34µ/g Hb while the control was 14.44±3.27µ/g Hb. The results 
showed that G-6-PD activity in type 2 diabetic patien s was significantly lower (p<0.05) compared to the control 
subjects. This finding therefore suggests that there is a decrease in G-6-PD activity in type 2 diabetic patients. For 
that reason, monitoring of G-6-PD activity may be an important tool in preventing diabetic injury due to
inappropriate antioxidation process. 
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Diabetes mellitus (DM) is a chronic metabolic 
disorders characterized by high levels of sugar 
(glucose) in the blood (David and Gardner, 2011). It 
is said to occur when the pancreas does not produce 
enough insulin or when the body cannot effectively 
use the insulin it produces and hence, an increased 
concentration of glucose in the blood known as 
hyperglycaemia (Warrell et al., 2005; David and 
Gardner, 2011). Although an estimated 16 million 
people in the United States are known to be affected, 
worldwide, more than 140 million people suffer from 
diabetes, making it one of the most common non 
communicable diseases (Zimmet et al., 2005). 
According to the American Diabetes Association 
(2003), DM is said to be associated with increased 
thirst, dehydration, weight loss, blurred vision, 
fatigue and occasionally comma. By implication, DM 
is a leading cause of end-stage renal disease, adult
onset blindness, and non traumatic lower extremity 
amputations in many parts of the world. 
 
The World Health Organization (1999) has classified 
three main types of DM. The Type 1 DM; which was 
previously referred to as "insulin-dependent diabetes 
mellitus" (IDDM) or "juvenile diabetes" (Lambert 
and Bingley, 2002) results from the body's failure to 
produce insulin and presently requires the person to 
inject insulin or wear an insulin pump. The majority 
of type 1 diabetes is of the immune-mediated nature, 
in which beta cell loss is a T-cell-mediated 
autoimmune attack (Rother, 2007). The Type 2 DM; 
which was previously referred to as non insulin-
dependent diabetes mellitus (NIDDM) or "adult-onset 
diabetes" is said to results from insulin resistance, a 
condition in which cells fail to use insulin properly, 
sometimes combined with an absolute insulin 
deficiency or relatively reduced insulin secretion 
(David and Gardner, 2011). The third form; 
gestational diabetes, occurs when pregnant women 
without a previous diagnosis of diabetes develop a 
high blood glucose level. It may precede 
development of type 2 DM (Cooke and Plotnick, 
2008). Other forms of diabetes mellitus include 
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congenital diabetes, which is due to genetic defects of 
insulin secretion, cystic fibrosis-related diabetes, 
steroid diabetes induced by high doses of 
glucocorticoids, and several forms of monogenic 
diabetes (Cooke and Plotnick, 2008; Lawrence et al., 
2008). 
 
Glucose-6-phosphate dehydrogenase (G-6-PD) is an 
enzyme in the pentose phosphate pathway, a 
metabolic pathway that supplies energy to a number 
of cells (notably erythrocyte) and maintained the 
level of the coenzyme – Nicotinamide adenine 
dinucleotide phosphate (NADPH) (Takizawa et al., 
1986). It catalyses the entry of glucose-6-phosphate 
into the pentose phosphate shunt and in the case of 
the red cells, this alternate anaerobic pathway for 
glucose metabolism is the only source of reduced 
NADPH, which is required for methaemoglobin 
reductase activity and the maintenance of the level of 
reduced glutathione. NADPH and reduced 
glutathione in turn maintain an effective redox 
potential, protecting cell membrane sulfhydryl group, 
enzymes and haemoglobin against oxidative stress 
(Takizawa et al., 1986). 
 
Glucose-6-phosphate dehydrogenase (G-6-PD) 
deficiency is a recessive X-link trait, placing males at 
highest risk for symptomatic diseases and this often 
manifested in several distinct clinical patterns 
(Gomez-Gallego, 2000). Inherited as an X-linked 
disorder, G-6-PD deficiency affects 400 million 
people worldwide (Gaskin et al., 2001). Glucose-6-
phosphate dehydrogenase (G-6-PD) deficiency in the 
alternative pathway causes the build-up of glucose 
and theus there is an increase of advanced glycation 
end products (AGE), it also causes a reduction of 
NADPH which is necessary for the formation of 
nitric oxide (NO) (Gaskin et al., 2001). The disease is 
highly polymorphic with more than 300 reported 
variants. It confers protection against malaria, which 
accounts for its high gene frequency (Cappellini and
Fiorelli, 2008). Most common is haemolysis after 
exposure to oxidative stress which could be due to 
ingestion of certain drugs or food (eg fava beans) or 
exposure to oxidant free-radicals generated by 
leucocytes during infection (Gomez-Gallego, 2000). 
 
Previous study by Gaskin et al., (2001) has related 
the high prevalence of type 2 diabetes mellitus and
hypertension in blacks in the West with G-6-PD 
deficiency. Hence, this study assesses the activity of 
glucose-6-phosphate dehydrogenase in patients with 




MATERIALS AND METHODS 
 
Study duration: This four (4) months study was 
carried out between September 2011 and January 
2012 at Irrua Specialist Teaching Hospital (ISTH), 
Irrua. 
 
Study population: ISTH located in Irrua the Local 
Government Head Quarter of Esan Central Local 
Government Area (ECLGA) of Edo State. It is the 
teaching Hospital of the Ambrose Alli University and 
serves as a referral institute for urban and rural 
population. 
 
Subjects: Subjects enrolled for the study comprised a 
total of one hundred (100) subjects, made up of sixty 
(60) type 2 diabetes mellitus patients (test) and forty 
(40) apparently healthy individuals (control) groups. 
 
Ethical consideration: Ethical approval was sought 
and given by the research and Ethic Committee of 
ISTH, Irrua while informed consent was obtained 
from willing participants. 
 
Sample collection: After an informed consent was 
obtained from subjects, four milliliters of blood 
samples were collected by venipuncture technique 
from subjects (both test and control). 2 ml of the 
sample collected was dispensed into EDTA and 
fluoride oxalate bottles each, properly swirled to 
avoid clotting. 
 
Assay: The glucose concentrations of the samples 
were determined using glucose oxidase-peroxidase 
(GOPD) method and the haemoglobin concentration 
were estimated colorimetrically using Drabkin’s 
solution. G-6-PD activity was estimated using 
enzymatic colourimetric method described by Lohr 
and Waller, (1974).  
 
Statistical analysis: The data obtained were analysed 
statistically, the Mean±standard deviation values 
were calculated in each case. The Students t- test 
statistical method was employed for comparison 
using SPSS software package version 16.0. A P-value 
(p≤0.05) was considered statistically significant at 




Table 1 shows the mean glucose concentration of 
diabetes mellitus (277.33±122.44mg/dl) and that of 
its counterpart apparently healthy subjects 
(67.36±6.61mg/dl). The mean G-6-PD activity of 
patients with type 2 diabetes mellitus was lower 
when compared with the non diabetic control group. 
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Specifically, the mean G-6-PD activity of patient 
with type 2 diabetes mellitus was shown to be 
2.53±1.34 µ/g Hb while that of the control subjects 
(non diabetes group) was 14.44±3.27 µ/g Hb. This 
difference in mean G-6-PD activity between type 2 
diabetes mellitus group and non-diabetes group 
(control) was significantly different (p<0.05).
 
 
Table 1: Glucose concentration and G-6-PD activity of patients with type 2 diabetes mellitus (test) and 
apparently healthy subjects (control) groups 
 
Parameters  Control (n=60) Test (n=60) t-value  p-value 








G-6-PD activity (µ/g Hb) 14.44±3.27 2.53±1.34* 21.89 < 0.05 
 
Results are mean ± standard deviation; values in a row having different superscript is statistically different (p≤0.05) 




Diabetes mellitus is a common and complicated 
metabolic disorder/disease. Studies indicate that 
blood glucose and its oxidant derivatives have a key 
role in the pathogenesis of diabetes mellitus (Haffner 
et al., 1998). Specifically, the activity of enzyme 
“glucose–6–phosphate dehydrogenase” (G-6-PD), an 
antioxidant system, has been reported to be important 
in preventing the complications of diabetes mellitus 
(Hamitton et al., 2004). 
 
In the present investigation, the G-6-PD activity in 
type 2 diabetic patients was significantly lower 
(p<0.05) compared to the non-diabetic subjects. This 
finding is in agreement with the reports of Wan et al., 
(2002) and Gwo-Hwa et al., (2002) who reported 
significantly lower activity of G-6-PD in type-2 
diabetic individuals. Hence, unsuitable control of 
blood glucose may decreases G-6-PD activity and 
increases diabetes mellitus complications. This can 
be attributed to the fact that, G-6-PD deficiency 
predisposes affected individuals highly susceptible to 
oxidative stress, which is one of the risk factors for 
diabetes. 
 
Gupta et al (1997), in a similar survey showed that
erythrocytic G-6-PD activity was lower in diabetic 
rats compared to healthy rats. It was reported that the 
enzyme activity gradually rose to normal limit after 
insulin administration (Gupta et al., 1997). The 
finding of this study was however at variance with 
the work of Joshi et al. (2001) where they observed a 
slight increase in the activity of G-6-PD in patiens 
with type-2 diabetes mellitus.  
 
Several surveys have also concluded that 
hyperglycaemia resulting from resistance to insulin, 
leads to increase of cAMP. This may activate protein 
kinase A, which causes inhibition and 
phosphorylation of G-6-PD activity and decreases 
NADPH as reported by Zhang et al., (2002). 
However, significant increase in G-6-PD mutations in 
the ketosis prone diabetes (KPD) population has been
implicated, suggesting that G-6-PD deficiency alone 
does not predispose individuals to ketosis-prone 
diabetes (Mauvais et al., 2004). Therefore, the 
significant reduction of G-6-PD activity in type 2 
diabetic patients may be due to the long episode of 
hyperglycaemia which was absent in the control 
subjects. 
 
Diabetic hyperglycaemia may lead to serious 
complications and decrease G-6-PD activity through 
glycation process and oxidative stress. This itself 
aggravates diabetic injury due to inappropriate 
antioxidation process. Therefore, patients with type 2 
diabetes mellitus who are G-6-PD deficient should 
avoid exposure to foods and drugs that can trigger 
haemolysis as this may result in haemolytic episode 





We sincerely appreciate the efforts of all, who 





American Diabetes Association (ADA) (2003). 
Hyperglycaemia Crisis patients with diabetes 
mellitus. Diabetes care., 26(11):33-550. 
 
Cappellini,M.D. and Fiorelli, G.T. (2008). Glucose-
6-phosphate dehyddrogenase deficiency. Lancet., 
371(9606):64-74. 
International Journal of Community Research http://www.anrescentpub.com 
ISSN: 2315 – 6562 
 
 Festus et al.; Vol 1 (2): 45 – 48  48 
 
Cooke, D.W. and Plotnick, L. (2008). "Type 1 
diabetes mellitus in pediatrics". Pediatr Rev., 29 (11): 
374–384.  
 
David, G. and Gardner, D. (2011). Greenspan's basic 
and clinical endocrinology (9th ed.). New York: 
McGraw-Hill Medical. pp. Chapter 17.  
 
Gaskin, R.S., Estwick, D.U. and Peddi, R. (2001). 
Glucose-6-phosphate dehydrogenase deficiency: its 
role in high prevalence of hypertension and diabetes. 
Ethnicity and disease., 11(4):749-754. 
 
Gomez-Gallego, F. (2000). Structural defects 
underlying protein dysfunction in human glucose-6-
phosphate dehydrogenase A (-) deficiency. Journal of 
Biochemistry., 275:2956. 
 
Gupta, B.L., Nehal, M. and Baquer, N.Z. (1997). 
effects of experimental diabetes on the activities of 
hhexokinase, glucose-6-phosphate dehydrogenase 
and catecholamines in rat erythrocytes of different 
ages. Indian journal of Experimental Biology., 
35:792-955. 
 
Gwo-Hwa, H., Shu-Chen, T. and Daniel, T. C. 
(2002). Decreased blood activity of G-6-PD 
associated with risk of diabetes mellitus. Post 
graduate Medical Journal., 19 (2):191-195. 
 
Haffner, S.M., Lehto S, Ronnemaa T., Pyorala K. and 
Laakso M. (1998). Mortality from coronary heart 
disease in subjects with type 2 diabetes mellitus and 
non diabetic subjects with and without prior 
myocardial infarction. New England Journal of 
Medicine; 23;339 (4). 229 – 234. 
 
Hamilton, J.W., Jones, F.G. and McMulin, M.F. 
(2004). Glucose -6-phosphate dehydrogenase 
deficiency Guadalajara- A case of chronic non-
sperocytic haemolytic anaemia responding to 
splenectomy and the role of splenectomu in this 
disorder. Haematology; 9 (4): 307 – 309. 
 
Joshi, S. R., Petel, R. Z., Sukumar, S. H. and Cocah, 
R. B. (2001). High prevalence of glucose -6- 
phosphate dehydrogenase deficiency in Vataliya 
Prajapati Community in Western India. 
Haematology., 31:57 – 60.    
 
Lambert, P. and Bingley, P. J. (2002). "What is Type 
1 Diabetes and its symptoms?". Medicine., 30: 1–5.  
 
Lawrence, J.M., Contreras, R., Chen, W. and Sacks, 
D.A. (2008). "Trends in the prevalence of preexisting 
diabetes and gestational diabetes mellitus among a 
racially/ethnically diverse population of pregnant 
women, 1999–2005". Diabetes Care., 31 (5): 899–
904. 
 
Lohr, G. W. and waller, H. D. (1974). glucose-6 –
phosphate dehydrogenase, method of enzymatic 
analysis. Varlag Chemie, Wehenheim., 3:636.  
 
Mauvais-Jarvis, F., Sobogwi, E., Porcher, R., Veriau, 
P. and Gutier, J. (2004). Ketosis –prone type 2 
diabetes in patients of Sub-Saharan African Origin. 
In: Clinical pathophysiology and natural history of β 
– Cell Dysfunction and Insulin Resistance. Diabetes. 
53:645 – 653.    
 
Rother, K.I. (2007). "Diabetes treatment—bridging 
the divide". The New England Journal of Medicine., 
356 (15): 1499–1501.  
 
Takizawa, I.T., Huang, L.U., Ikuta, T.Z. and 
Yoshida, L.A. (1986): Human glucose-6-phhosphate 
dehydrogenase primary structure and cDNA cloning. 
National Academy on Science. U.S.A., 83(4):265-273. 
 
Wan, G.H., Tsai, S.C. and Chiu, D.T. (2002). 
Decreased blood activity of glucose-6-phosphate 
dehydrogenase associated with increased risk of 
diabetes mellitus. Endocrine., 19:191-195. 
 
Warrell, A., David, A., Timothy, M., Cox, D., Firth, 
E. and Edward, B. (2005). Oxford Textbook of 
Medicine. Vol. 3. Oxford University Press. Pp. 720 – 
725. 
 
World Health Organisation (WHO). (1999). 
Definition, Diagnosis and Classification of Diabetes 
Mellitus and its Complications" (PDF). Pp. 12-14 
 
Zhang, Z., Apse, K. and Pang, J. (2002). High 
glucose inhibits glucose-6-phosphates dehydrogenase 
via cAMP in aortic endothelial cells. Journal of 
Biological Chemiistry., 275:40042-40047. 
 
Zimmet, P., Albert, K. and Shaw, J. (2001). Global 
and societal implications of the diabetes Epidemic. 
Nature., 414 (6865): 7823-7827. 
AUTHORS’ CONTRIBUTIONS  
Festus OO., supervised this study with the assistance 
of Dada FL., Iweka FK., Eyaufe AO., Osagie RN. 
and Akiyang EE. All authors were involved in the 
preparation of this article. 
 
